| 81.65 -0.2 (-0.24%) | 06-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 102.5 | 1-year : | 119.72 |
| Resists | First : | 87.76 | Second : | 102.5 |
| Pivot price | 80 |
|||
| Supports | First : | 78.97 | Second : | 73.54 |
| MAs | MA(5) : | 81.18  |
MA(20) : | 79.96 |
| MA(100) : | 78.54 |
MA(250) : | 80.89 |
|
| MACD | MACD : | 0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 77.5 |
D(3) : | 73.9 |
| RSI | RSI(14): 55 |
|||
| 52-week | High : | 99.5 | Low : | 61.18 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ANIP ] has closed below upper band by 33.6%. Bollinger Bands are 28.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 84.07 - 84.38 | 84.38 - 84.63 |
| Low: | 80.49 - 80.88 | 80.88 - 81.2 |
| Close: | 81.27 - 81.87 | 81.87 - 82.35 |
ANI Pharmaceuticals, Inc. operates as a biopharmaceutical firm, concentrating on the development, production, and commercialization of both proprietary (branded) and unbranded (generic) prescription medications across the United States and Canada. The company's primary focus areas include manufacturing controlled substances, treatments for oncology, hormones and steroids, injectable drugs, and various other pharmaceutical preparations. Its robust manufacturing capabilities encompass a range of dosage forms, such as oral solid products, semi-solids, liquid formulations, and topical agents, as well as highly potent compounds. Furthermore, ANI Pharmaceuticals provides contract development and manufacturing services to other pharmaceutical enterprises. The company distributes its products through a diverse network, which includes retail pharmacy chains, wholesalers, distributors, mail-order pharmacies, and group purchasing organizations. Incorporated in 2001, its corporate headquarters are situated in Baudette, Minnesota.
Thu, 11 Jun 2026
Insider Sell: Thomas Haughey Sells 2,000 Shares of ANI Pharmaceu - GuruFocus
Wed, 10 Jun 2026
ANI Pharmaceuticals (ANIP) director receives 4,357-share restricted stock award - Stock Titan
Wed, 10 Jun 2026
ANI Pharmaceuticals (ANIP) director awarded 4,357 restricted shares vesting in 2027 - Stock Titan
Wed, 10 Jun 2026
Ani Pharmaceuticals director Thomas Haughey sells $161,760 in stock By Investing.com - Investing.com UK
Wed, 10 Jun 2026
Ani Pharmaceuticals director Thomas Haughey sells $161,760 in stock - Investing.com
Wed, 10 Jun 2026
Should You Buy ANI Pharmaceuticals at 9.8x Forward Earnings? - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 23 (M) |
| Shares Float | 19 (M) |
| Held by Insiders | 6.8 (%) |
| Held by Institutions | 110.2 (%) |
| Shares Short | 3,620 (K) |
| Shares Short P.Month | 3,490 (K) |
| EPS | 3.91 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 26.34 |
| Profit Margin | 9.9 % |
| Operating Margin | 16.2 % |
| Return on Assets (ttm) | 4.9 % |
| Return on Equity (ttm) | 18.3 % |
| Qtrly Rev. Growth | 20.5 % |
| Gross Profit (p.s.) | 24.71 |
| Sales Per Share | 40.63 |
| EBITDA (p.s.) | 8.68 |
| Qtrly Earnings Growth | 86 % |
| Operating Cash Flow | 209 (M) |
| Levered Free Cash Flow | 140 (M) |
| PE Ratio | 20.88 |
| PEG Ratio | 0 |
| Price to Book value | 3.09 |
| Price to Sales | 2 |
| Price to Cash Flow | 8.89 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|